Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
PHASE2CompletedINTERVENTIONAL
Enrollment
185
Participants
Timeline
Start Date
March 31, 2004
Primary Completion Date
May 31, 2007
Study Completion Date
December 31, 2008
Conditions
Colorectal CancerMetastatic Cancer
Interventions
BIOLOGICAL
Panitumumab
Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
NCT00083616 - Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy | Biotech Hunter | Biotech Hunter